Novo Nordisk Soars, Johnson & Johnson Drops, ServiceNow Falls - podcast episode cover

Novo Nordisk Soars, Johnson & Johnson Drops, ServiceNow Falls

Dec 23, 20253 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

On this episode of Stock Movers:
- Novo Nordisk (NOVOB) won approval to sell a pill version of its obesity shot Wegovy in the US, to help people lose weight or maintain previous weight loss over the long term. The company will start selling the pill in the US in early January, and it is approved based on the results of the Oasis 4 trial, which found people taking the pill lost about 13.6% of their body weight over 64 weeks.
- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company's talc-based baby powder for causing her asbestos-linked cancer.
- ServiceNow Inc. has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares have fallen over 4% on the news.

See omnystudio.com/listener for privacy information.

Transcript

Speaker 1

Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report, your roundup of companies making moves in the stock market. Harnessing the power of Bloomberg data, take a look at some of the stocks that are on the move today. We can do that with Bloomberg's normal nd it nor what are you looking at?

Speaker 2

Well, let's look through one of the biggest stories of the day. We did see that Novo Nordists want approval to sell a pill version of its OBCD shot with GOVI in the United States. So this of course should help people lose weight or maintain their previous weight loss over the long term. But this is really an edge up against Eli Lay, its competitor, because it's essentially giving it a head start because Eli laly said that its own oral OBCD drug could be approved by March, so

this is getting in a bit earlier. You're seeing shares of Novo Nordist take her envy O reflecting that we see shares up as much as eleven percent, not pairing up about eight and a half percent. But this is the biggest jump since January on a single day basis. Yeah, definitely big news for Nova Nordisk.

Speaker 1

Seeing the healthcare space.

Speaker 2

Yeah, I'm also looking at shares of Johnson and Johnson. That's ticker Jay and Jay. We're seeing shares that are down just a smidge, about six tenths of a percent. This is after the company was ordered to pay about one point five six billion dollars to a marilynd woman who blamed the company's talk based baby powder for causing

her asbestos linked cancer. So we are hearing from researchers that they have linked asbestos to mesothelioma, and jurors did find that Jay and Jay and two of its units and its spinoff Kenview were liable for failing to warn the woman of its baby powder being tainted with asbestos. So you are seeing shares citing just a touch off of.

Speaker 1

The news Service now little M and a.

Speaker 2

Yeah, a little M and A action here on this What is this Tuesday? Hey, we did see the Service now This is ticker inow. It reached a deal to buy the cybersecurity startup Armis. The deal was valued at about seven point seventy five billion dollars. This is its largest acquisition to date for the company. So Service Now will pay in cash for Armis, expects to fund the transaction combo of cash on hand and debt. They said that the deal should close in about the second half

of twenty twenty six. We did see shares of the service now those sliding as much as two point nine percent earlier. Now it's down about two point three percent as we speak.

Speaker 1

The Stockmovers report from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street and for the latest market moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg dot com, and on Applecarplay and Android Auto with the Bloomberg Business app.

Transcript source: Provided by creator in RSS feed: download file
For the best experience, listen in Metacast app for iOS or Android